Tandem Diabetes Care (TNDM) Liabilities and Shareholders Equity (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 25.08% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $3.8 billion (changed 0.0% YoY), and the FY2025 full-year result was $881.1 million, down 8.94% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, up from $881.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.2 billion in Q1 2026 and bottomed at $874.7 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $952.7 million (2023), against an average of $968.0 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity jumped 34.6%; it then retreated 10.27% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2022, then declined by 9.51% to $952.7 million in 2023, then increased by 1.57% to $967.7 million in 2024, then retreated by 8.94% to $881.1 million in 2025, then surged by 30.9% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $881.1 million (Q4 2025), and $874.7 million (Q3 2025), per Business Quant data.

Peer Comparison